Movement disorders with neuroleptic drug treatment

Psychiatric Clinics of North America

Volumn 7, Issue 3, 1984, Pages 453-471

  Tarsy, D ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMANTADINE; AMPHETAMINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; APOMORPHINE; BACLOFEN; BENZATROPINE MESILATE; BROMOCRIPTINE; BUTAPERAZINE; BUTYROPHENONE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DANTROLENE; DIAZEPAM; DIPHENHYDRAMINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LEVODOPA; LITHIUM; MOLINDONE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PHYSOSTIGMINE; PROBENECID; PROPRANOLOL; RESERPINE; SUXAMETHONIUM; THIORIDAZINE; TIOTIXENE; VALPROIC ACID;

ADVERSE DRUG REACTION; AKATHISIA; CENTRAL NERVOUS SYSTEM; DYSKINESIA; HUMAN; INTOXICATION; NERVOUS SYSTEM; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; PARKINSONISM; REVIEW; TARDIVE DYSKINESIA;

EID: 0021128966     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0193-953x(18)30744-5     Document Type: Review

References (41)

1. Ayd F.R. Jr. A survey of drug-induced extrapyramidal reactions J.A.M.A. 175 1981 102 108
2. Baldessarini R.J. Cole J.O. Davis J.M. Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association Am. J. Psychiatry 137 1980 1163 1172
3. Burke R.E. Fahn S. Jancovic J. Tardive dystonia: Late onset and persistent dystonia caused by antipsychotic drugs Neurology 32 1982 1335 1346
4. Burke R.E. Fahn S. Mayeux R. Neuroleptic malignant syndrome caused by dopamine-depleting drugs, in a patient with Huntington’s disease Neurology 31 1981 1022 1026
5. Caroff S.N. The neuroleptic malignant syndrome J. Clin. Psychiatry 41 1980 79 83
6. Carter C.J. Pycock C.J. Studies on the role of catecholamines in the frontal cortex Br. J. Pharmacol. 42 1978 402P
7. Chase T.N. Schur J.A. Gordon E.K. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders Neuropharmacology 9 1970 265 275
8. Clow A. Jenner P. Marsden C.D. Changes in dopamine mediated behavior during one year’s neuroleptic administration Eur. J. Pharmacol. 57 1979 365 375
9. Crow T.J. Cross A.J. Johnstone E.C. Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol. 2 1982 336 340
10. Delay H. Deniker P. Drug-induced extrapyramidal syndromes Vinken P.J. Bruyn G.W. Diseases of the Basal Ganglia 1968 Elsevier-North Holland Amsterdam 248 266
11. DiMascio A. Demirgian E. Antiparkinson drug overuse Psychosomatics 11 1970 596 601
12. Gardos G. Cole J.O. Tarsy D. Withdrawal syndromes associated with antipsy chotic drugs Am. J. Psychiatry 135 1978 1321 1324
13. Garver D.L. Davis J.M. Dekiremenjian H. Pharmacokinetics of red blood cell phenothiazine and clinical effects Arch. Gen. Psychiatry 33 1976 862 866
14. Gelenberg A.J. Amantadine in the treatment of benztropine-refractory extrapyramidal disorders induced by antipsychotic drugs Curr. Ther. Res. 23 1978 375 380
15. Gelenberg A.J. Mandel M.R. Catatonic reactions to high-potency neuroleptic drugs Arch. Gen. Psychiatry 34 1977 947 950
16. Gessa R. Tagliamonte A. Gessa G.L. Blockade by apomorphine of haloperidol-induced dyskinesia in schizophrenic patients Lancet 2 1972 981 982
17. Granato J.E. Stern B.J. Ringel A. Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine Ann. Neurol. 14 1983 89 90
18. Henderson V.W. Wooten G.F. Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology 31 1981 132 137
19. Jeste D.V. Wyatt R.J. Understanding and Treating Tardive Dyskinesia 1982 Guilford Press New York
20. Kane J.M. Smith J.M. Tardive dyskinesia: Prevalence and risk factors, 1959–1979 Arch. Gen. Psychiatry 39 1981 473 481
21. Keepers G.A. Clappison V.J. Casey D.E. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes Arch. Gen. Psychiatry 40 1983 1113 1117
22. Kolbe H. Clow A. Jenner P. Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors Neurology 31 1981 434 439
23. Lipinski J.F. Zubenko G.S. Barreira P. Propranolol in the treatment of neuroleptic-induced akathisia Lancet 2 1983 685 686
24. Manos N. Gziouzepas J. Logethetis J. The need for continuous use of antiparkin sonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy Am. J. Psychiatry 138 1981 184 188
25. Marsden D.C. Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs Psychol. Med. 10 1980 55 72
26. Marsden C.D. Tarsy D. Baldessarini R.J. Spontaneous and drug-induced movement disorders in psychotic patients Benson D.F. Blumer D. Psychiatric Aspects of Neurologic Disease 1975 Grune and Stratton New York 219 266
27. McGeer P.L. McGeer E.G. Aging and extrapyramidal function Arch. Neurol. 34 1977 33 35
28. Meldrum B.S. Anlezark G.M. Marsden C.D. Acute dystonia as an idiosyncratic response to neuroleptics in baboons Brain 100 1977 313 336
29. Paulson G.W. Rizvi C.A. Crane G.E. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines Clin. Pediatr. 14 1975 953 955
30. Polizos P. Engelhardt D.M. Hoffman S.P. Neurological consequences of psychotropic drug withdrawal in schizophrenic children J. Autism Child. Schizophr. 3 1973 247 253
31. Rifkin A. Quitkin F. Klein D.F. Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder Arch. Gen. Psychiatry 32 1975 672 674
32. Regestein Ģ.R. Alpert J.S. Reich P. Sudden catatonic stupor with disastrous outcome J.A.M.A. 233 1977 618 620
33. Smego R.A. Durack D.T. The neuroleptic malignant syndrome Arch. Intern. Med. 142 1982 1183 1185
34. Smith J.M. Baldessarini R.J. Changes in prevalence, severity, and recovery in tardive dyskinesia with age Arch. Gen. Psychiatry 37 1980 1368 1373
35. Tarsy D. History and definition of tardive dyskinesia Clin. Neuropharmacol. 6 1983 91 100
36. Tarsy D. Baldessarini R.J. Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines Neuropharmacology 13 1974 927 940
37. Tolosa E.S. Clinical features of Meige’s disease (idiopathic orofacial dystonia) Arch. Neurol. 38 1981 147 151
38. Tom N. Matsuda O. Makiguch K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs J. Nerv. Ment. Dis. 169 1981 324 327
39. Van Pīaag H.M. Korf J. Importance of dopamine metabolism for clinical effects and side effects of neuroleptics Am. J. Psychiatry 133 1976 1171 1176
40. Van Putten T. The many faces of akathisia Compr. Psychiatry 16 1975 43 47
41. Willner H. Nagakawa M. Controversies in malignant hyperthermia Semin. Neurol. 3 1983 275 282